ArticlePloS one2025
Terahertz spectrum-based refractive index sensor for brain lesion detection using photonic crystal fibers.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Design and Optimization of Refractive Index-based Spiral Shape Twin-core Photonic Crystal Fiber Sensor for Detection of Blood Components.Cell biochemistry and biophysics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous types of brain lesions, cancers, and tumors are still thought to be lethal. An accurate photonic-based biological sensor that is capable of differentiate between normal and pathological brain tissues is presented in this work. Here, we use the defective two-dimensional photonic crystal to theoretically investigate the brain lesion detection. By monitoring the red shift of the wavelength of resonance that occurs as the layer of cerebral lesions' RI (Refractive Index) shifts from 1.38 to 1.4591, the device's execution is confirmed. The outcomes of the simulation using the proposed detector architecture yield very high relative sensitivity values of 98.54%, 98.84%, 99.049% and 97.075%; low EML values of 0.00359 cm-1, 0.00323 cm-1, 0.00297 cm-1, 0.00533 cm-1 for Low Grade Glioma, Glio-blastoma, Lymphoma and Normal brain cell, respectively, at a 2.2 THz frequency regime. Furthermore, the simulation results for each of the cancer cases stated point to a remarkably minimal CL (Confinement Loss) of 6.315 × 10-15 dB/cm. Through its ability to sense even minute fluctuations in RI, our planned sensor facilitates the identification of tumor at low concentrations. Because of its rapid reflexes, it can monitor the quantities of Low Grade Glioma, Glio-blastoma, Lymphoma and Normal brain cell instantly, which is essential to act rapidly in dangerous situations. In general, the efficacy, accuracy, and versatility of newly developed PCF sensors make them valuable tools for the reliable detection of Low Grade Glioma, Glio-blastoma, Lymphoma and Normal brain cell in a range of contexts, enhancing safety and surveillance protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.